Grants and Contributions:
Title:
Feasibility - Development of a preclinical formulation of the OpKemo therapeutic vector to treat solid tumors
Agreement Number:
980232
Agreement Value:
$179,500.00
Agreement Date:
Nov 1, 2021 - Mar 31, 2023
Description:
Development of a silica-based therapeutic vector to increase the efficacy and reduce the toxicity of certain drugs used to treat cancer.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Quebec, Quebec, CA G1P 4S6
Reference Number:
172-2021-2022-Q3-980232
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
743257313
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 151 days.
Amendment Date
Oct 5, 2022
Recipient's Legal Name:
Pharma In Silica inc.
Federal Riding Name:
Québec
Federal Riding Number:
24059
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: